Stabilized ACE2 Variant Disulfide Bond for COVID-19 Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The wild-type Ace2 protein has low stability in the soluble state, making it challenging to develop effective therapeutic agents for COVID-19, especially against SARS-CoV-2 virus mutant strains, as antibodies may not function properly against non-target strains due to specific antigen binding limitations.
Innovation Solution
A stabilized Ace2 variant is created by introducing disulfide bonds through cysteine substitution at specific amino acid residue pairs, enhancing the protein's stability and maintaining high binding affinity to the SARS-CoV-2 virus, and an Ace2-Fc fusion protein is developed by linking the stabilized variant to an immunoglobulin Fc domain for improved therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type Ace2 protein is used as a therapeutic agent, then it can bind to SARS-CoV-2 spike protein, but its stability is low in soluble state making it difficult to apply therapeutically
Solution Approach 1:
The patent introduces disulfide bonds at specific cysteine positions (e.g., C54, C124, C239, C343, C604) to alter the structural parameters of Ace2, transforming it from a low-stability soluble protein to a high-stability variant that maintains both solubility and binding affinity. This parameter change in molecular structure resolves the contradiction between binding function and structural stability.
2Reliability
If antibodies are used to bind specific antigens on SARS-CoV-2, then they can neutralize the virus, but they cannot work properly against mutant strains other than the target virus
Solution Approach 1:
The stabilized Ace2 protein serves as a universal therapeutic agent that can bind to the conserved receptor-binding domain of SARS-CoV-2 spike protein across multiple variants (including Alpha, Beta, Gamma, Delta, and Omicron). Unlike variant-specific antibodies, this single therapeutic maintains broad-spectrum effectiveness, achieving multi-functionality against diverse viral strains.
3Stability of the object's composition
If Ace2 protein is modified to improve stability, then shelf stability and therapeutic effect are improved, but the complexity of protein engineering increases
Solution Approach 1:
The patent applies targeted point mutations introducing disulfide bonds at five specific cysteine positions, which is a relatively simple and focused engineering approach. This controlled modification strategy achieves significant stability improvement without excessive complexity, balancing engineering effort with therapeutic benefit.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilized Ace2 variant exhibits enhanced stability and binding affinity, providing effective prevention and treatment of COVID-19, including against mutant strains, with improved shelf stability and therapeutic effects, and the Ace2-Fc fusion protein induces immune responses and extends drug retention in the body.
Implementation Method 1
a stabilized Ace2 variant comprising a disulfide bond formed by substituting cysteine for one or more of the amino acid residue pairs present in an Ace2-derived protein
Implementation Method 2
the high binding affinity between the spike protein on the surface of SARS-CoV-2 and the Ace2 protein
Implementation Method 3
the Ace2-Fc fusion protein induces immune responses and extends drug retention in the body
Data Source
AI summary
A stabilized Ace2 variant has a disulfide bond introduced by substituting cysteine for amino acid residue pairs at specific positions of the Ace2 protein, thereby having excellent stability. The stabilized Ace2 variant exhibits high binding affinity for SARS-CoV-2 virus and excellent stability even in an aqueous solution condition. When the stabilized Ace2 variant is applied to a therapeutic agent for COVID-19, which is the SARS-CoV-2 infectious disease, the shelf stability, in-vivo stability, and therapeutic effect of the therapeutic agent may all be improved. In addition, since it uses the amino acid sequence derived from the receptor for SARS-CoV-2, it may effectively work even against various virus mutant strains.